Upstream Bio (UPB) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Upstream Bio (UPB) over the past year, gaining 45.9% versus a loss of 76.3%. Zentalis Pharmaceuticals is the larger company by market cap ($259.0 million vs $257.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | UPB | ZNTL |
|---|---|---|
| Share price | $4.70 | $2.64 |
| Market cap | $257.42M | $259.04M |
| 1-day change | +3.30% | +5.18% |
| YTD return | -82.69% | +95.56% |
| 1-year return | -76.25% | +45.86% |
| 5-year return | — | -96.48% |
| EPS (TTM) | $-2.88 | $-2.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.68 | $6.95 |
| 52-week low | $4.37 | $1.21 |
| Distance from 52-week high | -86.05% | -62.01% |
| Analyst consensus | none | buy |
| Avg. price target upside | +562.55% | +177.65% |
| Average volume | 647.42K | 1.21M |
| Shares outstanding | 54.77M | 98.12M |
| Employees | 75 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed UPB by 122.1 percentage points over the past year.
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
UPB vs ZNTL FAQ
Which is bigger, Upstream Bio or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $259.04M compared with $257.42M for Upstream Bio (UPB).
Which stock has performed better over the past year, UPB or ZNTL?
ZNTL returned +45.86% over the past 12 months, compared with -76.25% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Upstream Bio and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.